Tvardi Therapeutics financials
$1.28−3.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 |
|---|---|
| Revenue | $0.00 |
| Gross profit | $0.00 |
| Gross margin | — |
| Operating income | -$26.7M |
| Net income | -$18.2M |
| Net margin | — |
| Diluted EPS | $-3.26 |
| EBITDA | -$26.7M |
| Operating cash flow | -$23.5M |
| Free cash flow | -$23.5M |
| Diluted shares | 7.8M |
Balance sheet
| Period end | Dec 31 |
|---|---|
| Cash & equivalents | $20.7M |
| Short-term investments | $10.1M |
| Total debt | $0.00 |
| Total assets | $32.1M |
| Total liabilities | $11.1M |
| Shareholders' equity | $20.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology